Attor­ney Gen­er­al Pax­ton Sues Yelp Over Dis­crim­i­na­tion Against Cri­sis Preg­nan­cy Centers

Texas Attorney General Ken Paxton has filed a lawsuit against Yelp after the company violated Texas’s Deceptive Trade Practices Act by appending inaccurate and misleading language to listings on pregnancy resource centers appearing in the search results on Yelp’s app and website.

September 28, 2023 | Press Release

State­ment from Attor­ney Gen­er­al Ken Pax­ton Upon Rein­state­ment as Attor­ney Gen­er­al of Texas

“It is my great honor to be back to work this week. The Office of the Attorney General has redoubled our focus on countless issues facing the state, including opposing illegal immigration, defending election integrity, holding predatory corporations to account, and fighting for the rule of law against the Biden Administration’s executive overreach.

September 22, 2023 | Press Release

Texas Law Enabling Cit­i­zens to Sue Over Local Ordi­nances Pre-Empt­ed by State Laws Takes Effect

HB 2127, a Texas law passed this year to empower citizens to challenge local ordinances pre-empted by state law, goes into effect today, September 1.  

September 01, 2023 | Press Release

Texas Law For­bid­ding Gen­der Tran­si­tion” Hor­mone and Sur­gi­cal Inter­ven­tions for Minors Takes Effect

SB 14, a state law passed this year to prohibit drug and surgical “gender transition” interventions for minors, goes into effect today, September 1.

September 01, 2023 | Press Release

Office of the Attor­ney Gen­er­al Files Appeal to Texas Supreme Court, Block­ing Dis­trict Judge’s Rul­ing and Uphold­ing Pro­tec­tions For Chil­dren From Gen­der Tran­si­tion” Procedures

The Office of the Attorney General (“OAG”) filed a Notice of Accelerated Interlocutory Appeal directly to the Texas Supreme Court in Loe, et al. v. State of Texas, et al, under Texas Civil Practice and Remedies Code Section 6.001(b) and Texas Rule of Appellate Procedure 29.1(b).

August 25, 2023 | Press Release

Office of the Attor­ney Gen­er­al Stays Travis Coun­ty Court’s Rul­ing Against Cru­cial Elec­tion Law By Fil­ing Direct Appeal to Texas Supreme Court

The Office of the Attorney General (“OAG”) today filed a Notice of Accelerated Interlocutory Appeal directly to the Texas Supreme Court under Texas Government Code section 22.001(c) in Harris County v. State of Texas et al.

August 15, 2023 | Press Release

Major Com­pa­ny Revers­es ESG Cred­it Rat­ing Prac­tice, A Vic­to­ry for Texas Efforts Against Improp­er Polit­i­cal Activism By Finan­cial Companies

In a victory for the State of Texas and consumers nationwide affected by financial companies prioritizing ideological “environmental, social, and corporate governance” (“ESG”) considerations over purely financial factors, S&P Global Ratings announced it would no longer publish new ESG credit indicators or update outstanding ESG credit indicators.

August 14, 2023 | Press Release

Spe­cial Lit­i­ga­tion Chief Leif Olson Departs Texas Attor­ney General’s Office to Serve as Iowa Chief Deputy Attor­ney General

Leif Olson, who has served as Chief of the Special Litigation Division since 2022, is departing to serve as Chief Deputy Attorney General for Iowa Attorney General Brenna Bird.

August 14, 2023 | Press Release

Office of the Attor­ney Gen­er­al Sues Trav­el Reser­va­tion Site for Decep­tive Trade Prac­tices Regard­ing the True Price of Hotel Rooms

The Office of the Attorney General of Texas (“OAG”) filed a lawsuit against Booking Holdings Inc. (“Booking”), a major travel reservation company, for engaging in false, misleading, or deceptive acts and practices in violation of the Texas Deceptive Trade Practices Act.

August 10, 2023 | Press Release

Office of the Attor­ney Gen­er­al’s Civ­il Med­ic­aid Fraud Divi­sion Recov­ers $42.7 Mil­lion in Tax­pay­er Funds

The Office of the Attorney General’s (“OAG”) Civil Medicaid Fraud Division settled an enforcement action brought under the Texas Medicaid Fraud Prevention Act (“TMFPA”) against pharmaceutical drug manufacturers Shire PLC, Baxter International Inc., Baxalta Inc., Viropharma Inc., Takeda Pharmaceuticals U.S.A., Inc., and Takeda Pharmaceuticals America.

August 08, 2023 | Press Release